Novo Nordisk's R&D goal is simple: we innovate to improve the lives of people living with serious chronic diseases. To achieve this, we work in close collaboration with leading universities and biotech companies worldwide, and we continually seek new partners with whom we share complementary capabilities and mutual interests. To every partnership we bring close to a century of experience in turning novel ideas into medicines, as well as in-house scientific capabilities spanning the entire pharmaceutical value chain.?
We offer our partners:
the entire pharmaceutical
Outstanding expertise in protein engineering, formulation and larger-scale production
World class clinical trial
To accelerate innovation, we openly share novel peptide and protein analogues as well as antibodies for preclinical research. We offer easy and free access to selected high-quality and well-characterized compounds to curious and passionate scientists from around the world.
“We are looking for partners who complement our own expertise, - or perhaps see new opportunities, and who are interested in collaborating with Novo Nordisk - to change patients’ lives, together.”
Lars Fruergaard J?rgensen,?
Chief Executive Officer
To foster more partnerships with local academic institutions and small biotech companies in China, we have launched INNOVO. Via the INNOVO platform, we will provide resources, technologies and platforms and together with potential partners we aim to create new innovation ecosystems.
We are looking for partners with complementary expertise in our therapy areas and adjacent disease areas – from novel modalities to technologies, and from early research to clinical stage.?
We are proud to have a team of highly skilled scientists lead the partnering process with external scientific partners. Learn more about the partnering process at Novo Nordisk in this small film.
At Novo Nordisk, we are highly focused on
pioneering innovation together with our external partners, and we are
broadening our commitment to a range of new collaborations, both
within our current therapy areas, and in new disease areas and
Novo Nordisk has acquired the rights to an early-stage glucose
binding molecule platform created by Ziylo Ltd, with the aim to
develop glucose responsive insulins. If successful, this development
could potentially eliminate the risk of hypoglycaemia for people with
Some of the research activities in Ziylo have been spun out in a new company, Carbometrics, which has entered into a research collaboration with Novo Nordisk to optimise glucose binding molecules.
“We believe the glucose binding molecules discovered by?the Ziylo team, together with Novo Nordisk’s world-class?insulin capabilities have the potential to lead?to the development of glucose responsive insulins, which?we hope can remove the risk of hypoglycaemia and ensure?optimal glucose control for people with diabetes.”
Novo Nordisk cooperates with institutions and authorities on
guidelines for research, animal experimentation and environmental
issues. Examples include our state-of-the-art housing conditions for
laboratory animals, which are referenced in the textbook?Comfortable Quarters for Laboratory Animals?and
on the webpages of?The National Centre for the Replacement, Refinement
and Reduction of Animals in Research.
Working with Novo Nordisk
"We have had the pleasure of receiving grants and working with many companies at our MIT lab. Novo Nordisk has been one of the very best companies to work with. I feel they’ve been tremendous collaborators, our students and staff have loved working with them, and enormous scientific progress has been made that I hope will benefit many patients someday.“?
Robert S. Langer?
Professor, Massachusetts Institute of Technology
Novo Nordisk is a global
provider of advanced treatments for diabetes and other serious
chronic diseases. We discover and develop innovative biological
medicines and make them accessible to patients throughout the world.